NEW YORK (360Dx) – Researchers at the University of Virginia School of Medicine and the University of Florida College of Medicine have developed a method to minimize false-negative test results that occur during immunoassay screening for benzodiazepine, a class of psychoactive drugs.

The method, described this week in The Journal of Applied Laboratory Medicine optimizes absorbance cutoff values, which are thresholds for determining whether a sample is sent for mass spectrometry confirmatory testing.